Dendreon (Nasdaq: DNDN) Priced Common Stock Offering

Dendreon Corporation (Nasdaq:DNDN) recently shared that it had priced its underwritten public offering of 15,000,000 shares of its common stock at a price to the public of $24.75 per share. Dendreon also granted to the underwriters a 30-day option to purchase up to an additional 2,250,000 shares of common stock to cover overallotments, if any. The offering is expected to close on December 15, 2009, subject to customary closing conditions.

Penny Stock Professor, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Penny Stock Picks.

J. P. Morgan Securities Inc. and Deutsche Bank Securities Inc. acted as joint book-running managers of the offering. Citigroup Global Markets Inc., Morgan Stanley & Co. Incorporated, Lazard Capital Markets LLC, Leerink Swann LLC and Needham & Company, LLC acted as co-managers. Dendreon anticipates net proceeds from the offering of approximately $356.0 million ($409.5 million if the underwriters exercise their overallotment option in full). Dendreon intends to use the net proceeds of the offering to fund expenditures in connection with the investment in its manufacturing facilities, including the accelerated build-out of new facilities in Atlanta, Georgia and Orange County, California (providing for additional capacity from such facilities in mid 2011) and build-out of the remaining capacity at its Morris Plains, New Jersey facility, to fund investment in information technology infrastructure and product support systems, to hire manufacturing, sales and marketing, quality and other personnel in preparation for the licensure by the FDA and commercialization of PROVENGE® (sipuleucel-T), for third-party contract supply costs, and for general corporate purposes, including working capital. The shares of common stock will be issued pursuant to Dendreon's effective registration statement on Form S-3 filed with the Securities and Exchange Commission (the "SEC"). Copies of the prospectus supplement and related base prospectus for this offering, when available, may be obtained by contacting: J.P. Morgan Securities Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by calling 1-866-803-9204; or Deutsche Bank Securities Inc., Prospectus Department, Harborside Financial Center, 100 Plaza One, Jersey City, New Jersey 07311-3988, or by calling 1-800-503-4611